GlaxoSmithKline Plc (GSK)

37.09
NYSE : Health Technology
Prev Close 37.09
Day Low/High 0.00 / 0.00
52 Wk Low/High 34.89 / 42.36
Avg Volume 3.00M
Exchange NYSE
Shares Outstanding 2.48B
Market Cap 91.82B
EPS 0.80
P/E Ratio 21.30
Div & Yield 2.12 (5.66%)

Latest News

Abbott, Glaxo, Casella and More: 'Mad Money' Lightning Round

Abbott, Glaxo, Casella and More: 'Mad Money' Lightning Round

Jim Cramer weighs in on Abbott, GlaxoSmithKline, Waste Management and more.

The Fed is In a Corner: Cramer's 'Mad Money' Recap (Thursday 12/7/18)

The Fed is In a Corner: Cramer's 'Mad Money' Recap (Thursday 12/7/18)

Investors are stressing about the economy and the Fed, which has little room to maneuver, Jim Cramer says.

Dow Ends Up Sharply; Stocks Rally on Easing Trade Tensions

Dow Ends Up Sharply; Stocks Rally on Easing Trade Tensions

U.S. stocks ended higher Monday after President Trump backed down from threats to impose additional tariffs on Chinese goods for 90 days while the countries work to negotiate a resolution to ongoing trade disputes.

GlaxoSmithKline Makes $5.1 Billion Play for Cancer Drug Specialist Tesaro

GlaxoSmithKline Makes $5.1 Billion Play for Cancer Drug Specialist Tesaro

GlaxoSmithKline said Monday that it's agreed to buy ovarian cancer drug specialists Tesaro for around $5.1 billion.

Tesaro (TSRO) Alert: Johnson Fistel Investigates Proposed Sale Of Tesaro, Inc. To GlaxoSmithKline Plc; Are Shareholders Getting A Fair Deal?

Tesaro (TSRO) Alert: Johnson Fistel Investigates Proposed Sale Of Tesaro, Inc. To GlaxoSmithKline Plc; Are Shareholders Getting A Fair Deal?

SAN DIEGO, Dec. 3, 2018 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Tesaro, Inc.

Pfizer Shares Jump on Monday After Company Signals Higher Price Push

Pfizer Shares Jump on Monday After Company Signals Higher Price Push

Pfizer pushes higher on price increases.

Tech Selloff Could Work in Favor of Pharmaceutical Stocks

Tech Selloff Could Work in Favor of Pharmaceutical Stocks

Pharma could be the best parking spot for your money if the market keeps trending downward.

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.

Once-daily Trelegy Ellipta Gains Expanded COPD Indication In Europe

Once-daily Trelegy Ellipta Gains Expanded COPD Indication In Europe

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has authorised an expanded label for once-daily Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI'), recognising its...

Drug Stocks Climb as Investors Digest Midterm Election Results

Drug Stocks Climb as Investors Digest Midterm Election Results

A split Congress is the best-case scenario for the drug industry, several analysts said.

Novice Trade: EWU United Kingdom ETF

Novice Trade: EWU United Kingdom ETF

This at-the-money, long put shooter is a high risk trade, so use discretionary capital.

Novice Trade: EWU ETF

Novice Trade: EWU ETF

This portfolio cannot be trusted to be diversified enough.

GlaxoSmithKline Gets a Boost

GlaxoSmithKline Gets a Boost

Drugmaker's charts show positive signs ahead.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ELON, EVRI, GSK, ITGR, MRAM, NPO, PLNT, QIWI, RUN, SFM, WIT Downgrades: ALEX, CVM, METC, SBGI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Gilead's Earnings Fail to Impress

Gilead's Earnings Fail to Impress

The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.

ViiV Healthcare Announces SWORD 100-week Data For Juluca (dolutegravir/rilpivirine) At AIDS 2018

ViiV Healthcare Announces SWORD 100-week Data For Juluca (dolutegravir/rilpivirine) At AIDS 2018

ViiV Healthcare today presented 100-week results from its phase III programme evaluating the safety and efficacy of switching virologically-suppressed people living with HIV (PLHIV) from a three or four-drug antiretroviral regimen to a 2-drug regimen of...

ViiV Healthcare Presents Phase III Data At AIDS 2018 From Landmark GEMINI Studies Showing Two-Drug Regimen Of Dolutegravir And Lamivudine Has Similar Efficacy To A Three-Drug Regimen In Treatment Naïve HIV Patients, With No Emergence Of Resistance

ViiV Healthcare Presents Phase III Data At AIDS 2018 From Landmark GEMINI Studies Showing Two-Drug Regimen Of Dolutegravir And Lamivudine Has Similar Efficacy To A Three-Drug Regimen In Treatment Naïve HIV Patients, With No Emergence Of Resistance

ViiV Healthcare today presented at the 22 nd International AIDS conference in Amsterdam 48-week results from the phase III GEMINI 1 & 2 studies, assessing the safety and efficacy of a two-drug regimen (2DR) of dolutegravir (DTG) and lamivudine (3TC)...

GSK Shares Climb as Board Is Said to Mull Breakup of Pharma Giant

GSK Shares Climb as Board Is Said to Mull Breakup of Pharma Giant

The pharmaceutical giant's American depository receipts jumped on the heels of a report that the company's chairman is mulling a breakup of the firm.

GlaxoSmithKline Is a Healthy Choice for Income Investors

The pharmaceuticals giant yields 4.85% and has lots of things going for it.

Elliott Tackles AC Milan After Chinese Investors Falter; Pfizer Eyes Reorg-ICYMI

Elliott Tackles AC Milan After Chinese Investors Falter; Pfizer Eyes Reorg-ICYMI

Here's what you need to know now for Wednesday, July 11.

Pfizer Announces Big Reorganization As It Continues Trying to Sell Consumer Biz

Pfizer Announces Big Reorganization As It Continues Trying to Sell Consumer Biz

The changes will take effect at the start of 2019.

Creates Act Clears Committee Vote, Could Ease Way for Generic Drugmakers

Creates Act Clears Committee Vote, Could Ease Way for Generic Drugmakers

While the CREATES ACT passed out of committee in the Senate, Senator Orrin Hatch, who helped pave the way for generic drugs in the U.S,,voted against the measure.

Mylan Slumps in After-Hours Trading on Generic Advair Update

Mylan Slumps in After-Hours Trading on Generic Advair Update

The drugmaker says the FDA will issue a complete response letter on June 27.

GSK Submits Regulatory Application In Japan For Once-Daily Single Inhaler Triple Therapy FF/UMEC/VI For Patients With COPD

GSK Submits Regulatory Application In Japan For Once-Daily Single Inhaler Triple Therapy FF/UMEC/VI For Patients With COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for once-daily fluticasone furoate/umeclidinium/vilanterol...

Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward

President Trump's appetite for TV and ratings is legendary and now the administration wants to require drug company TV ads to include the list price of prescription drugs.

20 Top Stocks From Around the World With an Average 25% Upside Potential

20 Top Stocks From Around the World With an Average 25% Upside Potential

In this market, picking the right stocks is paramount. Here is a tidy list of top ideas from the strategy team at HSBC.

What to Expect From Allergan, Aetna, Merck and Pfizer's Earnings Next Week

What to Expect From Allergan, Aetna, Merck and Pfizer's Earnings Next Week

The drugmakers and health insurer are preparing to unveil first-quarter numbers.

Walgreens, Arena Pharma, Dominion Energy: 'Mad Money' Lightning Round

Walgreens, Arena Pharma, Dominion Energy: 'Mad Money' Lightning Round

Jim Cramer focuses on Walgreens Boots Alliance, Arena Pharmaceutical, Dominion Energy, Tower Semiconductor, Idexx, LexinFintech Holdings and more.

TheStreet Quant Rating: B- (Buy)